177 related articles for article (PubMed ID: 15897553)
21. LABAZ1: A metastatic tumor model for renal cell carcinoma expressing the carbonic anhydrase type 9 tumor antigen.
Zisman A; Pantuck AJ; Bui MH; Said JW; Caliliw RR; Rao N; Shintaku P; Berger F; Gambhir SS; Belldegrun AS
Cancer Res; 2003 Aug; 63(16):4952-9. PubMed ID: 12941820
[TBL] [Abstract][Full Text] [Related]
22. Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene.
Hernández JM; Bui MH; Han KR; Mukouyama H; Freitas DG; Nguyen D; Caliliw R; Shintaku PI; Paik SH; Tso CL; Figlin RA; Belldegrun AS
Clin Cancer Res; 2003 May; 9(5):1906-16. PubMed ID: 12738749
[TBL] [Abstract][Full Text] [Related]
23. Carbonic anhydrase IX expression in clear cell renal cell carcinoma and normal tissues: experiences from (radio) immunotherapy.
Brouwers AH; Mulders PF; Oyen WJ
J Clin Oncol; 2008 Aug; 26(22):3808-9; author reply 3811-2. PubMed ID: 18669472
[No Abstract] [Full Text] [Related]
24. Kidney cancer: Carbonic anhydrase IX in resected clear cell RCC.
Pickering LM; Larkin J
Nat Rev Urol; 2015 Jun; 12(6):309-10. PubMed ID: 26032554
[No Abstract] [Full Text] [Related]
25. Carbonic anhydrase IX expression in clear cell renal cell carcinomas negatively correlates with the proportion of the granular cell component.
Skapa P; Hyrsl L; Zavada J; Soukup J; Zamecnik J
J Clin Oncol; 2008 Aug; 26(22):3809-11; author reply 3811-2. PubMed ID: 18669473
[No Abstract] [Full Text] [Related]
26. Prognostic implications of polymorphisms and interleukin-2 therapy for renal cell carcinoma.
Gardner TA; Logan T
J Urol; 2009 Aug; 182(2):425-6. PubMed ID: 19524946
[No Abstract] [Full Text] [Related]
27. [Detection of carbonic anhydrase IX gene expression in renal cell carcinoma with reverse transcription-PCR].
Jiang YD; Zheng SB; Wang ZH
Di Yi Jun Yi Da Xue Xue Bao; 2004 Jan; 24(1):99-101. PubMed ID: 14724112
[TBL] [Abstract][Full Text] [Related]
28. Carbonic anhydrase expression in kidney and renal cancer: implications for diagnosis and treatment.
Oosterwijk E
Subcell Biochem; 2014; 75():181-98. PubMed ID: 24146380
[TBL] [Abstract][Full Text] [Related]
29. The use of positron-emission tomography in the diagnosis of tumour phenotype.
Divgi C
BJU Int; 2008 Jun; 101 Suppl 4():36-8. PubMed ID: 18430121
[No Abstract] [Full Text] [Related]
30. Carbonic anhydrase IX: historical and future perspectives.
Oosterwijk E
BJU Int; 2008 Jun; 101 Suppl 4():2-7. PubMed ID: 18430115
[No Abstract] [Full Text] [Related]
31. Carbonic anhydrase IX expression is associated with improved outcome of high-dose interleukin-2 therapy for metastatic renal cell carcinoma.
Dudek AZ; Yee RT; Manivel JC; Isaksson R; Yee HO
Anticancer Res; 2010 Mar; 30(3):987-92. PubMed ID: 20393025
[TBL] [Abstract][Full Text] [Related]
32. CA9 gene expression in conventional renal cell carcinoma: a potential marker for prediction of early metastasis after nephrectomy.
Li G; Feng G; Gentil-Perret A; Genin C; Tostain J
Clin Exp Metastasis; 2007; 24(3):149-55. PubMed ID: 17390110
[TBL] [Abstract][Full Text] [Related]
33. Long-term stability of T-cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cells.
Lamers CH; van Elzakker P; van Steenbergen SC; Luider BA; Groot C; van Krimpen BA; Vulto A; Sleijfer S; Debets R; Gratama JW
Cytotherapy; 2013 May; 15(5):620-6. PubMed ID: 23388583
[TBL] [Abstract][Full Text] [Related]
34. A potential for tissue restrictive gene therapy in renal cell carcinoma using MN/CA IX promoter.
Ou YC; Gardner TA; Kao C; Zhau HE; Chung LW
Anticancer Res; 2005; 25(2A):881-6. PubMed ID: 15868923
[TBL] [Abstract][Full Text] [Related]
35. Targeting aggressive cancers with an artificial sweetener: could saccharin be a lead compound in anticancer therapy?
Mahon BP; Okoh CO; McKenna R
Future Oncol; 2015; 11(15):2117-9. PubMed ID: 26235178
[No Abstract] [Full Text] [Related]
36. The role of carbonic anhydrase IX overexpression in kidney cancer.
Dorai T; Sawczuk IS; Pastorek J; Wiernik PH; Dutcher JP
Eur J Cancer; 2005 Dec; 41(18):2935-47. PubMed ID: 16310354
[TBL] [Abstract][Full Text] [Related]
37. Circulating large extracellular vesicles carrying CA9 in the diagnosis and prognosis of clear-cell renal cell carcinoma.
Vergori L; Martinez MC; Bigot P
Clin Transl Med; 2021 Mar; 11(3):e358. PubMed ID: 33783991
[No Abstract] [Full Text] [Related]
38. Re: C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
Ramsey S; Aitchison M
J Urol; 2005 Dec; 174(6):2422-3. PubMed ID: 16280863
[No Abstract] [Full Text] [Related]
39. G250: a carbonic anhydrase IX monoclonal antibody.
Lam JS; Pantuck AJ; Belldegrun AS; Figlin RA
Curr Oncol Rep; 2005 Mar; 7(2):109-15. PubMed ID: 15717944
[TBL] [Abstract][Full Text] [Related]
40. Deregulation of energetic metabolism in the clear cell renal cell carcinoma: A multiple pathway analysis based on microarray profiling.
Soltysova A; Breza J; Takacova M; Feruszova J; Hudecova S; Novotna B; Rozborilova E; Pastorekova S; Kadasi L; Krizanova O
Int J Oncol; 2015 Jul; 47(1):287-95. PubMed ID: 25998032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
